GE Healthcare Introducing Brochure

GE Healthcare

Introducing Q.Suite

The value of PET/CT in diagnostic
imaging has been established
for years — but now, even brighter
possibilities are coming to light.
With new quantitative tools that
generate more consistent PET
measurements, clinicians can
now assess treatment response
more accurately than ever before.
As a result, clinicians can forge
a bold new treatment paradigm:
personalized care.

It’s all about finding the most
effective treatment sooner, based
on each patient’s response. It’s
the future of PET/CT. And the tools
within Q.Suite are designed to
help make it a reality.

Together with our customers,
we are focused on improving
cost, quality and access in
PET imaging — a smarter path
to tomorrow’s care.

Personalized care: Effective treatments, tangible results

During the course of cancer treatment, clinicians
traditionally gauge progress by looking for physical
change in the size of a tumor, typically using CT or MR.
But with quantitative PET imaging, they can also
consider metabolic activity. Often times, metabolic
changes in a tumor can be perceived more quickly than
physical ones, so quantitative PET can give physicians
an earlier view of how well a treatment is working.

This is the key to personalized care. By getting answers
sooner, clinicians can modify treatment strategies
without waiting for physical results, potentially
increasing the chance of an effective therapy. More
effective therapy may help improve your patient’s
quality of life and overall outcome as well as reduce
the cost burden of ineffective treatment.

For quantitative PET to be effective, clinicians need
consistent SUV measurements between a patient’s
baseline scan and subsequent follow-up scans on a
single scanner. Variation can occur throughout the
PET workflow, in areas from patient management and
biology to equipment protocols and performance.
Controlling these variables to increase consistency
can help improve your confidence that an SUV change
has true clinical meaning.